Intra-Cellular Therapies (ITCI) Announces Proposed Stock Offering
Get Alerts ITCI Hot Sheet
Join SI Premium – FREE
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it has commenced an underwritten public offering of $400 million of shares of its common stock. In connection with the offering, Intra-Cellular Therapies intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares in the offering will be sold by Intra-Cellular Therapies.
J.P. Morgan, SVB Leerink, BofA Securities, Evercore ISI and RBC Capital Markets are acting as joint book-running managers for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Intra-Cellular Therapies (ITCI) PT Raised to $107 at Canaccord Genuity
- SLM Corp. (SLM) PT Raised to $25 at RBC Capital
- Veralto Corp. (VLTO) PT Raised to $101 at RBC Capital
Create E-mail Alert Related Categories
Corporate News, Equity OfferingsRelated Entities
JPMorgan, The Children's Investment Fund (TCI), RBC Capital, S3Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!